Table 3.

Changes in creatinine post-biopsy by type of rejection

Group	1-Month Follow-up				2–3-Month Follow-up
	N	Month 0, Median (25th, 75th), mg/dl	Month 1, Median (25th, 75th), mg/dl	P	N	Month 0, Median (25th, 75th), mg/dl	Month 2–3, Median (25th, 75th), mg/dl	P
BPAR or treated rejection	21	2.3 (1.8, 2.8)	1.9 (1.5, 2.8)	0.75	23	2.2 (1.8, 2.9)	1.9 (1.5, 2.7)	0.92
Clinical (no BPAR)	10	2.1 (1.7, 2.5)	2.0 (1.4, 2.8)	0.80	8	2.1 (1.8, 2.4)	2.1 (1.7, 2.4)	0.55
ABMR	6	2.2 (1.8, 2.9)	2.2 (2.0, 3.0)	0.44	6	2.2 (1.9, 2.6)	1.8 (1.5, 2.1)	>0.99
TCMR	5	3.4 (2.1, 4.7)	1.8 (1.3, 1.9)	0.13	8	2.5 (2.0, 34)	1.8 (1.4, 3.6)	0.94
No BPAR or treated rejection	20	2.0 (1.6, 2.8)	1.9 (1.7, 2.6)	0.08	26	1.8 (1.7, 2.6)	1.8 (1.5, 2.1)	0.02

The study groups are listed in the first column. For each group, distribution of creatinine at time of biopsy, at first test at 1 mo, and after 2–3 mo is given, along with number of patients in each group with a creatinine measurement at that time point. Finally, a P value is given, showing whether creatinine exhibits a statistically significant change from time of biopsy to follow-up time for two different follow-up times: at 1 mo and at 2–3 mo. BPAR, biopsy–proven acute rejection; ABMR, antibody-mediated rejection; TCMR, T cell–mediated rejection.